Applied Genetic Technologies (AGTC) Misses Q4 EPS by 20c, Revenues Miss

Applied Genetic Technologies (NASDAQ: AGTC) reported Q4 EPS of ($0.37), $0.20 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $8.46 million.

“We have achieved significant progress across our broad and diverse portfolio of five ophthalmology development programs,” said Sue Washer, President and CEO of AGTC. “We expanded our clinical and medical leadership teams, maintained a robust balance sheet and ended our fiscal year with strong momentum having our highest annual enrollment in clinical trials to date.”

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance